Literature DB >> 17167111

Severe lupus nephritis: racial differences in presentation and outcome.

Stephen M Korbet1, Melvin M Schwartz, Joni Evans, Edmund J Lewis.   

Abstract

This study assessed whether certain clinicopathologic variables could explain the impact of race on outcome in 86 patients who had severe lupus nephritis and were available for long-term follow-up after participating in a prospective, controlled, clinical trial. Fifty-four (63%) patients were white, 21 (24%) were black, and 11 (13%) were categorized as other. The proportion of patients with anti-Ro, anti-nRNP, and anti-Sm was significantly greater among black patients. Biopsies with segmental active proliferative and necrotizing lesions that involved >or=50% of glomeruli +/- membranous glomerulonephritis (class III >or=50%+/-V) were significantly more common (white 44%, black 76%, other 36%; P < 0.05) and diffuse proliferative glomerulonephritis +/- membranous glomerulonephritis (class IV+/-V) was less common (white 54%, black 24%, other 64%) among black patients. Attainment of a remission was greatest among white patients (white 52%, black 29%, other 27%; P = 0.09). Features that were predictive of a remission were white race, baseline serum creatinine, and class IV+/-V lesions. Patient survival at 10 yr (white 81%, black 59%, other 73%; P = 0.029) and renal survival at 10 yr (white 68%, black 38%, other 61%; P = 0.015) were significantly poorer in black patients. Predictors of ESRD were serum creatinine, the presence of anti-Ro antibodies, class III >or=50%+/-V lesions, and failure to achieve a remission. In conclusion, racial differences were observed in the serologic and histologic features at presentation, response to treatment, and outcome of patients with severe lupus nephritis. In a population of patients with severe lupus nephritis, black patients were significantly more likely to have a serologic profile and renal lesions that were associated with more aggressive renal disease and resulted in worse outcomes than white patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167111     DOI: 10.1681/ASN.2006090992

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  80 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  Clinical presentation and outcomes of childhood-onset membranous lupus nephritis.

Authors:  Maria Pereira; Eyal Muscal; Karen Eldin; M John Hicks; Anna Carmela P Sagcal-Gironella; Marietta DeGuzman; Scott E Wenderfer
Journal:  Pediatr Nephrol       Date:  2017-07-17       Impact factor: 3.714

3.  Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.

Authors:  Duvuru Geetha; Caroline J Poulton; Yichun Hu; Philip Seo; Julie Anne G McGregor; Ronald J Falk; Susan L Hogan
Journal:  Semin Arthritis Rheum       Date:  2013-12-04       Impact factor: 5.532

4.  Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.

Authors:  Takayuki Katsuno; Takenori Ozaki; Takaya Ozeki; Asaka Hachiya; Hangsoo Kim; Noritoshi Kato; Takuji Ishimoto; Sawako Kato; Tomoki Kosugi; Naotake Tsuboi; Masashi Mizuno; Yasuhiko Ito; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2018-05-23       Impact factor: 2.801

5.  Glomerular disease: Lupus nephritis treatment: are we beyond cyclophosphamide?

Authors:  Brad H Rovin
Journal:  Nat Rev Nephrol       Date:  2009-09       Impact factor: 28.314

6.  Lupus or syphilis? That is the question!

Authors:  Joana Azevedo Duarte; Celia Coelho Henriques; Carolina Sousa; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-06-04

7.  Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States.

Authors:  Jinoos Yazdany; Candace H Feldman; Jun Liu; Michael M Ward; Michael A Fischer; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

Review 8.  An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases.

Authors:  Alice S Appel; Gerald B Appel
Journal:  Nat Clin Pract Nephrol       Date:  2009-01-27

9.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

Review 10.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.